The trial was made with the company’s lead candidate, CS1, in the rare cardiovascular disease Pulmonary Arterial Hypertension. See Sten R Sörensen, CEO, announce the results and their impact on Cereno Scientific.
See the interview at biostock.se:
https://www.biostock.se/en/2024/10/cereno-scientific-discusses-phase-iia-results-for-cs1/
This is a press release from BioStock – Connecting Innovation & Capital.
